Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial

Calithera Biosciences Inc CALA shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company's investigational arginase inhibitor, in adults with cystic fibrosis (CF).
The data were shared at the North American Cystic Fibrosis Foundation Conference (NACFC).
At NACFC, data were presented on the first 24 subjects (18 treated with CB-280, six with placebo) for 50mg BID, 100mg BID and 200mg BID dose levels.
CB-280 had a well-tolerated safety profile across all three dose levels, and all 18 subjects receiving CB-280 completed treatment without treatment interruptions or premature discontinuations.
A pooled analysis of treatment vs. placebo showed a positive trend in forced expiratory volume in one second (FEV1), a safety endpoint, compared to placebo.
Encouraging trends were seen in disease biomarkers, including increased FeNO and decreased sweat chloride.
The study is ongoing, with Cohort 4 (300mg BID) on track to complete enrollment by the end of 2021.
Read Next: Calithera Buys Two Oncology Candidates From Takeda For $45M.
Price Action: CALA shares are up 3.37% at $1.99 during the market session on the last check Monday.